Cancer-associated thromboembolism is a substantial problem in clinical practice. An increase in the level of fibrinopeptide A (a substance associated with hypercoagulable states) has been observed in humans exposed to fluorouracil. Anti-EGFR monoclonal antibodies cetuxi... View more
1. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014;7:CD006650.
2. Donnellan E, Kevane B, Bird BR, et al. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol 2014;21:134-43.
3. Elyamany G, Alzahrani AM, Bukhary E. Cancerassociated thrombosis: an overview. Clin Med Insights Oncol 2014;8:129-37.
4. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712-23.
5. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012;9:e1001275.
6. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-68.
7. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003;16: 21-31.
8. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 1 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124-9.
9. Gary T. Cancer related venous thromboembolism - prophylaxis and therapy. Vasa 2014;43:245-51.
10. Gomez D, De Rosa A, Addison A, et al. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? Int J Surg 2013; 11:507-13.